Blood cell counts during treatment of neuroendocrine tumors with [111-In-DTPA]octreotide

被引：0
|
作者：
van Hagen, PM
Valkema, R
Tse, WK
Kwekkeboom, DJ
de Herder, WW
Hooykaas, H
Krenning, EP
机构：
[1] Erasmus Univ, Dept Immunol, NL-3000 DR Rotterdam, Netherlands
[2] Erasmus Univ, Dept Nucl Med, NL-3000 DR Rotterdam, Netherlands
[3] Erasmus Univ, Dept Internal Med 3, NL-3000 DR Rotterdam, Netherlands
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE | 1999年 / 26卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
PS620
引用
收藏
页码：1207 / 1207
页数：1
相关论文
共 50 条
  • [31] 64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients
    Pfeifer, Andreas
    Knigge, Ulrich
    Binderup, Tina
    Mortensen, Jann
    Oturai, Peter
    Loft, Annika
    Berthelsen, Anne Kiil
    Langer, Seppo W.
    Rasmussen, Palle
    Elema, Dennis
    von Benzon, Eric
    Hojgaard, Liselotte
    Kjaer, Andreas
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (06) : 847 - 854
  • [32] Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases
    Georgios S. Limouris
    Achilles Chatziioannou
    Dimitrios Kontogeorgakos
    Dimitrios Mourikis
    Maria Lyra
    Panagiotis Dimitriou
    Anastasia Stavraka
    Athanassios Gouliamos
    Lambros Vlahos
    European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35 : 1827 - 1837
  • [33] 110mIn-DTPA-D-Phe1-octreotide for imaging of neuroendocrine tumors with PET
    Lubberink, M
    Tolmachev, V
    Widström, C
    Bruskin, A
    Lundqvist, H
    Westlin, JE
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (10) : 1391 - 1397
  • [34] Therapeutic efficacy and toxicity of In-111-DTPA-D-Phe-Octreotide in advanced neuroendocrine tumour patients
    Schipper, ML
    Gotthardt, M
    Béhé, M
    Arnold, R
    Behr, TM
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2003, 18 (02) : 292 - 292
  • [35] Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases
    Limouris, Georgios S.
    Chatziioannou, Achilles
    Kontogeorgakos, Dimitrios
    Mourikis, Dimitrios
    Lyra, Maria
    Dimitriou, Panagiotis
    Stavraka, Anastasia
    Gouliamos, Athanassios
    Vlahos, Lambros
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 (10) : 1827 - 1837
  • [36] OCTREOTIDE AS AN ANTINEOPLASTIC AGENT IN THE TREATMENT OF FUNCTIONAL AND NONFUNCTIONAL NEUROENDOCRINE TUMORS
    SALTZ, L
    TROCHANOWSKI, B
    BUCKLEY, M
    HEFFERNAN, B
    NIEDZWIECKI, D
    TAO, Y
    KELSEN, D
    CANCER, 1993, 72 (01) : 244 - 248
  • [37] Alternating lanreotide and octreotide in the treatment of metastatic neuroendocrine tumors (NETs)
    Koussis, H.
    Scola, A.
    Cirillo, F.
    Basso, U.
    Ziampiri, S.
    Casara, D.
    Pelizzo, M. R.
    Rebustello, F.
    Behboo, R.
    Jirillo, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [38] Intensification of In-111-DTPA-octreotide scintigraphy by means of pretreatment with cold octreotide in small cell lung cancer
    Soresi, E
    Invernizzi, G
    Boffi, R
    Possa, M
    Bombardieri, E
    Ciavarella, GP
    Liuzzi, A
    LUNG CANCER, 1997, 17 (2-3) : 231 - 238
  • [39] Personal dosimetry of the staff during treatment of neuroendocrine tumours with a high dose of indium-111 octreotide
    Stokkel, MPM
    Boot, IN
    Smit, JW
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE, 2002, 46 (04): : 331 - 335
  • [40] Ga-68 DOTATOC PET/CT and In-111-DTPA-Octreotide SPECT for staging of enteropancreatic neuroendocrine tumors: Evaluation of costs and consequential costs
    Schreiter, Nils
    Hamm, Bernd
    Nogami, Munenobu
    Pape, Ulrich-Frank
    Buchert, Ralph
    Brenner, Winfried
    Maurer, Martin
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52
12345